SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

11-02 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
09/09/26	SEK 19.12	-2.75%	43,241
08/09/26	SEK 19.66	+2.08%	190,369
07/09/26	SEK 19.26	+10.06%	476,203
04/09/26	SEK 17.50	+0.34%	634,397
03/09/26	SEK 17.44	-12.45%	502,924

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe Europe 13:34:23 09/09/2026 BST			5-day change	1st Jan Change
19.10 ^SEK	-2.85%		-4.02%	-15.40%

09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW

Market Cap	1.1B 115M 98.77M 92.92M 84.79M 158M 10.89B 159M 426M 5.57B 431M 422M 17.71B	P/E 2026 *	-11.7x	P/E 2027 *	-20.1x
Enterprise Value	1.13B 117M 101M 95.01M 86.71M 162M 11.14B 163M 436M 5.69B 441M 431M 18.11B	EV / Sales 2026 *	25.4x	EV / Sales 2027 *	54.4x
Free-Float	68.66%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SYNACT	Delayed
CBOE		Real-time
Deutsche Boerse AG	8F8	Delayed
Börse Stuttgart	8F8	Delayed
CBOE		Real-time
Tradegate	8F8	Real-time
Boerse Muenchen	8F8	Real-time

09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
09-07	Synact Pharma sees support for phase 3 after post hoc analysis	FW
09-07	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
09-03	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
09-03	Synact Pharma CEO and head of research sell shares for tax reasons	FW
08-28	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
08-28	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI
08-20	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Synact Pharma reports narrower operating loss	FW
08-20	Calendar Thursday, August 20	FW
08-19	Synact Pharma signs term sheet with Hipolabor on resomelagon in Brazil	FW
08-19	SynAct Pharma AB and Hipolabor Farmacêutica LTDA Sign Term Sheet for Co-Development and Commercialization Partnership for Treatment of Dengue In Brazil	CI

SynAct Pharma AB Share Price

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation : SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news : SynAct Pharma AB

Last Transcript : SynAct Pharma AB

Analysts' recommendations : SynAct Pharma AB

Press Releases : SynAct Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors : SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

09-08	SynAct Pharma : Bolagspresentation September 2026	PU
09-08	SynAct Pharma : Company presentation	PU
09-07	SynAct on phase III plans following new ADVANCE data	AQ
09-07	SynAct Pharma : Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development – FDA discussions on trial design planned for Q4 2026	PU
09-07	Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026	AQ

1 day	-2.75%
1 week	-4.02%
Current month	-4.40%
1 month	+1.59%
3 months	+33.15%
6 months	+4.82%
Current year	-15.40%

1 week	16.84	20.05
1 month	16.84	22.45
Current year	7.05	24.4
1 year	7.05	25.3
3 years	4.98	28.5
5 years	4.98	146
10 years	4.8	146

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	31/12/2013
Ann Kristin Led DFI	Director of Finance/CFO	-	28/02/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	14/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	19/03/2024
Anders Kronborg CHM	Chairman	62	19/03/2024
Sten Scheibye BRD	Director/Board Member	74	19/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/03/26	Anders Kronborg	Buy	Chairman	2,750	0.0052%
09/03/26	Mads Bjerregaard	Buy	Executive/Senior Manager	1,500	0.0028%
09/03/26	Quantass ApS	Buy	Company	7,900	0.0148%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-2.85%	-4.02%	-3.34%	+7.54%	115M
ELI LILLY AND COMPANY	-2.21%	-3.11%	+52.16%	+91.64%	1,002B
JOHNSON & JOHNSON	-2.22%	-0.76%	+51.08%	+67.61%	649B
ABBVIE INC.	-2.99%	-4.31%	+18.59%	+66.94%	440B
ROCHE HOLDING AG	-0.60%	-0.11%	+29.33%	+37.38%	346B
NOVARTIS AG	-0.39%	-15.26%	+9.03%	+26.01%	263B
ASTRAZENECA PLC	-1.46%	-1.82%	-1.82%	+11.96%	250B
AMGEN INC.	-10.08%	-10.26%	+40.32%	+51.55%	213B
NOVO NORDISK A/S	-1.22%	-4.38%	-14.84%	-57.82%	201B
GILEAD SCIENCES, INC.	-2.88%	-2.19%	+26.54%	+92.95%	182B
Average	-0.75%	-2.24%	+20.71%	+39.58%	354.38B
Weighted average by Cap.	-0.11%	-2.39%	+32.74%	+57.59%

	2026 *	2027 *
Net sales	44.25M 4.62M 3.97M 3.73M 3.41M 6.36M 438M 6.39M 17.12M 224M 17.34M 16.96M 712M	21.6M 2.25M 1.94M 1.82M 1.66M 3.1M 214M 3.12M 8.36M 109M 8.46M 8.28M 348M
Net income	-47.08M -4.91M -4.22M -3.97M -3.63M -6.77M -466M -6.8M -18.22M -238M -18.45M -18.05M -758M	-31.92M -3.33M -2.86M -2.69M -2.46M -4.59M -316M -4.61M -12.35M -161M -12.51M -12.23M -514M
Net Debt	24.81M 2.59M 2.23M 2.09M 1.91M 3.57M 245M 3.58M 9.6M 125M 9.72M 9.51M 399M	74.22M 7.74M 6.66M 6.26M 5.72M 10.67M 734M 10.72M 28.72M 375M 29.08M 28.44M 1.19B